MT1621

· Zogenix MDS, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MT1621, covering 2023-09-01 to 2023-09-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) [Phase 3]